Eli Lilly invests USD3.5B in Pennsylvania Plant to scale next-gen obesity drugs

USA—Eli Lilly has announced plans to invest more than USD 3.5 billion in building a large-scale manufacturing facility in Pennsylvania’s Lehigh Valley.

The new site will expand the company’s U.S. production capacity and strengthen domestic medical supply chains.

According to the company, the plant will produce injectable weight-loss medications, including the experimental drug retatrutide, which has shown record levels of weight loss in late-stage trials.

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.

In February 2025, the company announced its commitment to spend at least USD 27 billion on building four new U.S. production sites.

These investments add to the USD 23 billion Lilly has already allocated toward new facilities since 2020.

Next-generation drug development

Retatrutide is viewed as a key part of Lilly’s long-term obesity treatment strategy, following the success of its injection Zepbound and the anticipated launch of its obesity pill orforglipron.

Unlike older weight-loss treatments, retatrutide acts on three gut hormones simultaneously, which experts believe could help people with severe obesity achieve significantly greater weight reduction.

Lilly plans to release new data this year from seven ongoing Phase 3 trials involving the drug.

The new plant will play a central role in increasing the company’s manufacturing capacity to meet growing demand for these advanced therapies.

Lilly said construction on the Lehigh Valley site will begin later this year, and the facility is expected to become operational by 2031.

Competing in a booming market

The company’s expansion comes as demand for GLP-1 weight-loss drugs surges worldwide.

Lilly recently overtook Danish rival Novo Nordisk to claim the largest share of the U.S. obesity drug market.

Novo, however, aims to close that gap with the recent launch of the first-ever GLP-1 pill for obesity, which has already generated thousands of prescriptions.

Lilly’s competing obesity pill, orforglipron, could receive approval and enter the U.S. market later this year.

Both companies have struggled at times to keep up with soaring demand for their weekly injections, prompting new investment to prevent future shortages.

The added capacity from the new Pennsylvania site will help Lilly stay ahead in this highly competitive sector.

Economic and political dimensions

President Donald Trump has said that Lilly plans to build up to six U.S. manufacturing plants, though the company has not yet confirmed that figure.

The president previously threatened to impose tariffs on imported pharmaceuticals to encourage domestic production.

However, concerns over such penalties have eased since recent voluntary drug pricing agreements between the White House and major drugmakers, including Lilly and Novo Nordisk.

These agreements exempt the companies from import levies for at least three years.

Job creation and regional impact

The Pennsylvania project is expected to have a significant economic impact on the Lehigh Valley region.

Lilly said the new facility will create 850 permanent jobs, including positions for engineers, scientists, technicians, and operations staff.

The construction phase will also generate around 2,000 temporary jobs, boosting local employment and supporting Pennsylvania’s growing life sciences sector.

Governor Josh Shapiro described the investment as the largest by a life sciences company in Pennsylvania’s history.

He noted that the site was selected from more than 300 proposals, chosen for its strong infrastructure, skilled workforce, and proximity to leading universities.